Trial Profile
A biomarker study to evaluate whether the TLE3 is a useful marker for predicting the therapeutic effect of eribulin chemotherapy for triple-negative breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 23 Dec 2015 New trial record